Lenalidomide Eg

Lenalidomide, the active ingredient in Lenalidomide Eg, is an immunomodulatory drug (IMiD) presented as an oral formulation for oral use. It is employed in the treatment of certain hematologic malignancies, including multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma, typically in adult patients who have received prior therapies.

GNH USA supplies Lenalidomide Eg as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, oncology centres, pharmacies and clinics worldwide, sourced from the European Union market.

Lenalidomide is an immunomodulatory agent used in the management of specific hematologic cancers.

Multiple Myeloma: improves progression‑free survival and overall response rates in patients with relapsed or refractory disease. Myelodysplastic Syndromes: reduces transfusion dependence and delays transformation to acute leukemia in patients with del(5q) cytogenetic abnormality. Mantle Cell Lymphoma: induces tumor regression and extends survival in patients with relapsed or refractory disease.

Lenalidomide may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Fatigue: persistent tiredness. - Diarrhea: loose stools. - Nausea: sensation of queasiness. - Rash: mild skin eruptions.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Severe neutropenia: markedly reduced neutrophil count. - Hepatotoxicity: elevated liver enzymes or liver injury.

Lenalidomide requires careful monitoring and specific safety measures.

Pregnancy: contraindicated; teratogenic risk (Category X). Thrombosis risk: assess and consider prophylactic anticoagulation. Renal impairment: use with caution and monitor renal function. Hepatic dysfunction: monitor liver function tests regularly. Blood counts: perform baseline and periodic CBC to detect cytopenias. Store at ambient temperature: keep below 25 °C, in original container, protect from moisture and light.

Lenalidomide can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce lenalidomide exposure. - Anticoagulants (e.g., warfarin, DOACs): increased risk of thromboembolic events. - Immunosuppressants (e.g., cyclosporine): may enhance hematologic toxicity.

Moderate Interactions (Monitor Closely): - P-glycoprotein inhibitors (e.g., verapamil): may increase plasma levels. - NSAIDs: additive risk of renal impairment. - Live vaccines: may be less effective while on therapy.